secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001140361-23-045170
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis reports positive Phase 3 olezarsen results; 100% reduction in pancreatitis in FCS
--------------------------------------------------------------------------------

- Olezarsen 80 mg achieved primary endpoint with significant triglyceride reduction vs placebo (p=0.0009) at six months.
- Acute pancreatitis events reduced 100% (0 events for olezarsen vs 11 for placebo) over 12 months.
- Favorable safety profile; no hepatic/renal toxicity, no clinically meaningful platelet reductions.
- Ionis plans to file NDA with FDA early 2024; potential first approved treatment for FCS in US.
- Phase 3 studies continuing in broader severe hypertriglyceridemia (SHTG) population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036123045170/0001140361-23-045170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036123045170/ef20011263_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-045170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer